Literature DB >> 8370973

Expression and topography of integrins and basement membrane proteins in epidermal carcinomas: basal but not squamous cell carcinomas display loss of alpha 6 beta 4 and BM-600/nicein.

P Savoia1, L Trusolino, E Pepino, O Cremona, P C Marchisio.   

Abstract

The expression and topography of some integrins and basement membrane proteins in cutaneous basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) have been studied by immunohistochemistry and Western blotting. It has been shown that the typical cell-to-cell distribution of alpha 2 beta 1 and alpha 3 beta 1 found in normal epidermis is replaced by pericellular distribution in both BCC and SCC cells. BCC and SCC also showed different patterns of expression of alpha 6 beta 4, an integrin heterodimer normally lining the basal surface of basal epidermal keratinocytes: whereas SCC showed high expression and pericellular distribution of alpha 6 beta 4, BCC cells did not express this integrin at all. The absence of alpha 6 and beta 4 subunits from BCC extracts was confirmed by Western blotting. The molecular composition of the basement membrane was markedly different in the two types of epidermal tumors. Whereas laminin and collagen type IV were conserved in the basement membrane zone of both tumors, the molecular complex BM-600/nicein, which is recognized by the monoclonal antibody GB3 and is possibly identical to the previously described basement membrane glycoproteins kalinin and epiligrin, was absent from BCC cells. Then, the simultaneous loss of expression of alpha 6 beta 4 and BM-600/nicein in BCC cells but not in SCC cells indicates that alpha 6 beta 4 integrin and one of its potential ligands may be co-regulated in both BCC and SCC, thus suggesting a role for this phenomenon in the pathogenesis and clinical behavior of these epidermal tumors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370973     DOI: 10.1111/1523-1747.ep12365531

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Integrin-dependent amplification of the G2 arrest induced by ionizing radiation.

Authors:  Celeste L Kremer; Monika Schmelz; Anne E Cress
Journal:  Prostate       Date:  2006-01-01       Impact factor: 4.104

2.  Investigation into the mechanism of the loss of laminin 5 (alpha3beta3gamma2) expression in prostate cancer.

Authors:  J Hao; L Jackson; R Calaluce; K McDaniel; B L Dalkin; R B Nagle
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

Review 3.  Altered integrin expression and the malignant phenotype: the contribution of multiple integrated integrin receptors.

Authors:  M M Zutter; H Sun; S A Santoro
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-04       Impact factor: 2.673

4.  Altered Distribution and Expression of Syndecan-1 and -4 as an Additional Hallmark in Psoriasis.

Authors:  Eleni Koliakou; Manthou Maria Eleni; Ioanna Koumentakou; Nikolaos Bikiaris; Polyanthi Konstantinidou; Patricia Rousselle; Doxakis Anestakis; Elisabeth Lazaridou; Evangelia Kalloniati; Miliaras Dimosthenis; Anna Michopoulou
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

5.  Signal transduction by the alpha 6 beta 4 integrin: distinct beta 4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes.

Authors:  F Mainiero; A Pepe; K K Wary; L Spinardi; M Mohammadi; J Schlessinger; F G Giancotti
Journal:  EMBO J       Date:  1995-09-15       Impact factor: 11.598

Review 6.  Roles of Integrin α6β4 Glycosylation in Cancer.

Authors:  Yoshinobu Kariya; Yukiko Kariya; Jianguo Gu
Journal:  Cancers (Basel)       Date:  2017-07-05       Impact factor: 6.639

7.  Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing.

Authors:  G Zambruno; P C Marchisio; A Marconi; C Vaschieri; A Melchiori; A Giannetti; M De Luca
Journal:  J Cell Biol       Date:  1995-05       Impact factor: 10.539

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.